Visit
The 3rd International Workshop on Acute Leukemias (iwAL) 2021 took place on 28-30 April with VJHemOnc as official media partner. The workshop featured a global expert faculty, sharing the latest advances in acute leukemia through insightful presentations and live interactive panel discussions.
On-demand presentations and panel discussions with leading experts are now available to watch below.
Session topics include:
B- & T-ALL, MRD & Diagnostics, Immunotherapies, When to Place CAR-T in the Clinical Routine, Advances in AML biology, Controversies in AML, ASCT and post-ASCT Maintenance Approaches, MDS New Data/Novel Therapies, Mechanisms of Drug Resistance, To Target or Not in Elderly AML, Emerging Therapies in AML
iwAL 2021
The 3rd International Workshop on Acute Leukemias (iwAL) 2021
28–30 April 2021 | Virtual Meeting
iwAL 2021
The 3rd International Workshop on Acute Leukemias (iwAL) 2021
28–30 April 2021 | Virtual Meeting
The 3rd International Workshop on Acute Leukemias (iwAL) 2021 took place on 28-30 April with VJHemOnc as official media partner. The workshop featured a global expert faculty, sharing the latest advances in acute leukemia through insightful presentations and live interactive panel discussions.
On-demand presentations and panel discussions with leading experts are now available to watch below.
Session topics include:
B- & T-ALL, MRD & Diagnostics, Immunotherapies, When to Place CAR-T in the Clinical Routine, Advances in AML biology, Controversies in AML, ASCT and post-ASCT Maintenance Approaches, MDS New Data/Novel Therapies, Mechanisms of Drug Resistance, To Target or Not in Elderly AML, Emerging Therapies in AML
Session 1: Advances in T-ALL
Update in T-ALL biology
Jan Cools KU Leuven, Belgium, Belgium
Prognostic impact of T-ALL subtype
Jonathan Bond University College Dublin, Dublin, Ireland
CAR T-cells for T-ALL?
He Huang Zhejiang University, Hangzhou, China
COG AALL0434 in newly diagnosed t-cell ALL
Stuart Winter Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, United States
Session 1 panel discussion
Session 2: B-ALL
Scientific update in B-ALL
Charles Mullighan St. Jude Children’s Research Hospital, Memphis, TN, United States
Blinatumomab in frontline pediatric ALL
Patrick Brown Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States
Venetoclax plus navitoclax for ALL
Jeffrey Rubnitz St. Jude Children's Research Hospital, Memphis, TN, United States
Reducing T-cell exhaustion with CD19/CD3 BiTEs
Nora Zieger Ludwig Maximilian University of Munich, Munich, Germany
Session 2 panel discussion
Session 3: MRD & Diagnostics
Stratifying risk with MRD in ALL
Mignon Loh University of California, San Francisco, San Francisco, CA, United States
MRD in infant ALL
Janine Stutterheim Princess Máxima Center, Utrecht, Netherlands
Session 3 panel discussion
Session 4: ALL Immunotherapies
R/R ALL: BLINA or INO first? Which combinations? - Blinatumomab
Elias Jabbour University of Texas MD Anderson Cancer Center, Houston, TX, United States
R/R ALL: BLINA or INO first? Which combinations? - Inotuzumab
Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany
Session 4 panel discussion
Session 5: When to Place CAR-T in the Clinical Routine?
Managing toxicities in CAR T-cell ALL patients
Jordan Gauthier Fred Hutchinson Cancer Research Center, Seattle, WA, United States
CAR T-cell therapy followed by transplant in children/YAs
Daniel Lee University of Virginia, Charlottesville, VA, United States
A Synthetic T-Cell & Antigen Receptor (STAR) therapy for R/R B-ALL
Peihua Lu Lu Daopei Hospital, Beijing, China
Session 5 panel discussion
Session 6: Advances in AML Biology
Single cell genomics and AML
Koichi Takahashi The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
Stem Cells in Human AML
Ravindra Majeti Stanford University School of Medicine, Stanford, CA, United States
CHIP: Updates and Future Directions
Liran Shlush Weizmann Institute of Science, Rehovot, Israel
Session 6 panel discussion
Session 7: Controversies in AML
7+3 or VEN-AZA for complex karyotype AML: 7+3
Stéphane de Botton Gustave Roussy, Paris, France
7+3 or VEN-AZA for complex karyotype AML: VEN-AZA
Daniel Pollyea University of Colorado, Denver, CO, United States
7+3 or VEN-AZA panel discussion
Is it safe to delay initiation of induction? Yes
Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
Is it safe to delay initiation of induction? No
Gunnar Juliusson Lund University, Lund, Sweden
Delaying induction panel discussion
Session 8: ASCT and Post-ASCT Maintenance Approaches
Graft-versus-Leukemia biology
Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
MRD and AML
Christopher Hourigan National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States
UK Impact transplant trials
Charles Craddock University of Birmingham, Birmingham, United Kingdom
Optimizing the conditioning regimen in AML
Koichi Takahashi The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
Post-transplant maintenance therapy-where are we?
Victoria Potter King's College Hospital NHS Foundation Trust, London, United Kingdom
Novel immunotherapeutic strategies post BMT
John DiPersio Washington University School of Medicine, St. Louis, MO, United States
Session 8 panel discussion
Session 9: MDS New Data/Novel Therapies
Venetoclax and immune checkpoint blockade in MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Imetelstat and roxadustat in MDS
Valeria Santini University of Florence, Florence, Italy
APR-246 and magrolimab in MDS
Rami Komrokji H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Oral HMAs/Pevonedistat in MDS
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 9 panel discussion
Session 10: Mechanisms of Drug Resistance
FLT3 inhibitors
Catherine Smith University of California, San Francisco, San Francisco, CA, United States
Venetoclax
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
IDHi
Amir Fathi Massachusetts General Hospital Cancer Center, Boston, MA, United States
Gemtuzumab ozogamicin
Roland Walter Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Session 10 panel discussion
Session 11: To Target or Not in Elderly AML
FLT3 inhibitors in frontline FLT3 AML ineligible for intensive therapy - Pro
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
FLT3 inhibitors panel discussion
HMA-VEN or HMA-IDHi for frontline IDHm elderly AML?
Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States
IDHm AML panel discussion
Session 12: Emerging Therapies in AML
Molecular biomarkers and triplets with HMA-VEN
Marina Konopleva University of Texas MD Anderson Cancer Center, Houston, TX, United States
Anti-CD47
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Menin
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
RAR
Stéphane de Botton Gustave Roussy, Paris, France
Oral HMA
Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States
Session 12 panel discussion
Session 13: Immunotherapeutics in AML
Understanding immunobiology of AML
Ivana Gojo Johns Hopkins Medicine, Baltimore, MD, United States
BiTES
Marion Subklewe LMU Hospital Munich, Munich, Germany
Checkpoints
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
CAR-T
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
Session 13 panel discussion
Visit the AML channel for the latest updates from leading experts
